Dr. Ranjit Bindra an Indian American physician-scientist at Yale School of Medicine has been elected to the Connecticut Academy of Science and Engineering (CASE) for 2026.
Bindra, Co-Director of the Yale Brain Tumor Center at Smilow Cancer Hospital, and 7 different college members, are among the many main consultants in science, know-how, engineering, arithmetic, and drugs chosen for this yr’s cohort.
Election to CASE is open to scientists and engineers who work or stay in Connecticut. Consideration is predicated on “scientific distinction achieved through significant original contributions in theory or applications, unusual accomplishments in the pioneering of new and developing fields of applied science and technology, or both,” in accordance to the group.
The new members will likely be inducted on the academy’s 51st annual dinner to be held on May 19.
Read: SXSW 2026: Indian American innovators and creatives join global lineup in Austin, Texas
In the laboratory, Bindra’s group lately led a crew of 4 main laboratories at Yale, which reported the gorgeous discovery that IDH1/2-mutant tumors harbor a profound DNA restore defect that renders them exquisitely delicate to PARP inhibitors.
This work was revealed in Science Translational Medicine, and Nature, and it has obtained worldwide consideration with main scientific implications.
Dr. Bindra is now translating this work immediately into sufferers, in 4 section I/II scientific trials, together with an progressive, biomarker-driven trial particularly concentrating on the Adolescent/Young Adult (AYA) most cancers affected person inhabitants. In addition, he’s lead co-PI of a 35-site, NCI-sponsored Phase II trial testing the PARP inhibitor, olaparib, in grownup IDH1/2-mutant stable tumors.
As a biotech entrepreneur he lately co-founded Cybrexa Therapeutics, a Series B round-funded firm targeted on growing a completely new class of small molecule DNA restore inhibitors, which immediately goal the tumor microenvironment.
Dr. Bindra obtained his undergraduate diploma in Molecular Biophysics and Biochemistry from Yale University in 1998, and each his MD and PhD from the Yale School of Medicine in 2007. He accomplished his medical internship, radiation oncology residency, and post-doctoral analysis research on the Memorial Sloan-Kettering Cancer Center in 2012.